Reproductive Medicine Associates Of New Jersey Enters Multi Year Agreement With GeneGo, Inc. To Access MetaCore

Published: Jul 11, 2006

ST. JOSEPH, Mich., July 11 /PRNewswire-FirstCall/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Reproductive Medicine Associates (RMA) of New Jersey have licensed MetaCore to use for research and in their clinic. Primarily, MetaCore will be used for analysis of gene expression data from individual human oocytes and blastomers. It was important for RMA that MetaCore has comprehensive curated content in the area of reproduction and is capable of concurrent analysis of multiple patients' datasets.

"We are pleased to have acquired this excellent research tool from GeneGo. MetaCore will increase our ability to translate research discoveries into clinical applications that will improve the quality of life for patients with infertility," said Dr. Nathan Treff, Principle Investigator of Molecular Biology at RMA of New Jersey.

"We are very pleased to see our tools licensed by RMA," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore has been applied extensively in the area of reproductive medicine by several pharmaceutical companies and academic groups, but this is the first time it will be used by health care practitioners. This is very encouraging as our ultimate goal is to adapt systems data analysis technology to the needs of doctors and individual patients."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at

MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.

GeneGo, Inc.

CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756 7996,

Back to news